Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434696 | 0.84 | MAPT (0.44) | RAB9AMAPTCCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL265643 | 0.82 | KEAP1 (0.44) | RAB9AMAPTCCR1CCR5CCR8 | |
| SCHEMBL1428296 | 0.82 | ADRA2A (0.47) | RAB9AMAPTCCR1CCR5CCR8 | |
| SCHEMBL11099285 | 0.82 | ESR1 (0.49) | — | |
| SCHEMBL26802133 | 0.81 | RAB9A (0.42) | RAB9AMAPTCCR1CCR5CCR8 | |
| Potassium Ion SCHEMBL31201703 | 0.81 | RAB9A (0.42) | RAB9AMAPTCCR1CCR5CCR8 | |
| SCHEMBL14346900 | 0.81 | MAPT (0.42) | RAB9AMAPTCCR1CCR5CCR8 | |
| SCHEMBL24244764 | 0.79 | MAPT (0.41) | RAB9AMAPTCCR1CCR5CCR8 | |
| SCHEMBL10174364 | 0.79 | RAB9A (0.44) | RAB9AMAPTCCR1CCR5CCR8 | |
| SCHEMBL13948751 | 0.79 | KDM4E (0.41) | RAB9AMAPTCCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405453-B1 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2024-05-29 | — | — | EP | claimed |
| CN-108884032-B | Method for preparing poly (carbonate-etherimide) compounds | PTT全球化学股份有限公司 | 2021-10-15 | — | — | CN | claimed |
| US-10759904-B2 | Method for preparing poly(carbonate-etherimide) compound | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2020-09-01 | — | — | US | claimed |
| US-20190202980-A1 | METHOD FOR PREPARING POLY(CARBONATE-ETHERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2019-07-04 | — | — | US | claimed |
| EP-3405453-A2 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT Global Chemical Public Company Limited (TH) | 2018-11-28 | — | — | EP | claimed |
| EP-3405453-B1 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC CO LTD (TH) | 2024-05-29 | — | — | EP | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE | 2023-06-22 | — | — | US | disclosed |
| CN-108884032-B | Method for preparing poly (carbonate-etherimide) compounds | PTT全球化学股份有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-10759904-B2 | Method for preparing poly(carbonate-etherimide) compound | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2020-09-01 | — | — | US | disclosed |
| US-20190202980-A1 | METHOD FOR PREPARING POLY(CARBONATE-ETHERIMIDE) COMPOUND | PTT GLOBAL CHEMICAL PUBLIC COMPANY LIMITED (TH) | 2019-07-04 | — | — | US | disclosed |
| EP-3405453-A2 | A METHOD FOR PREPARING POLY(CARBONATE-ETH ERIMIDE) COMPOUND | PTT Global Chemical Public Company Limited (TH) | 2018-11-28 | — | — | EP | disclosed |
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20110071289-A1 | AMINOPYRAZOLE AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
| US-6521643-B1 | Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1157022-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000049015-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-24 | — | — | WO | disclosed |
| US-4365065-A | 1-(Pyridinyl)-2-(dimethylamino)ethenyl lower-alkyl ketones | STERLING DRUG INC. (US) | 1982-12-21 | — | — | US | disclosed |
| US-4313951-A | 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor | STERLING DRUG INC. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4312875-A | 5-(Pyridinyl)-6-(lower-alkyl)-2(1H)-pyridinones, 1,2-dihydro-2-oxo-5-(pyridinyl)-6-(lower-alkyl)nicotinic acids and lower-alkyl esters thereof, and cardiotonic use thereof | STERLING DRUG INC. (US) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | RAB9A 3644/4885MAPT 1613/4885CCR1 3091/4885 |
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | GPR119, GPR3, MRGPRX2 | RAB9A 1196/4885MAPT 4776/4885CCR1 666/4885 |
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SARS1, ACE2, ACE | RAB9A 974/4885MAPT 1318/4885CCR1 1254/4885 |
| US-20110071289-A1 | AMINOPYRAZOLE AMIDE DERIVATIVE | ARGLU1, ARG1, CNKSR1 | RAB9A 470/4885MAPT 3958/4885CCR1 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.